{"id":"allerslit-forte","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (erythema, swelling, pruritus)"},{"rate":null,"effect":"Systemic allergic reactions"},{"rate":null,"effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL3730724","moleculeType":"Small molecule","molecularWeight":"242.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an allergenic extract-based immunotherapy designed to modulate immune tolerance to environmental allergens. By administering progressively higher concentrations of allergen extract, the treatment aims to shift the immune response from IgE-mediated hypersensitivity toward IgG-mediated tolerance and regulatory T cell activation, thereby reducing allergic symptoms upon natural allergen exposure.","oneSentence":"Allerslit forte is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual exposure to increasing doses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:52.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis and/or allergic asthma caused by specific environmental allergens"}]},"trialDetails":[{"nctId":"NCT00841256","phase":"PHASE3","title":"Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-02","conditions":"Allergic Rhinoconjunctivitis","enrollment":207},{"nctId":"NCT00623701","phase":"PHASE3","title":"Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-03","conditions":"Allergy, Rhinitis, Conjunctivitis","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Allerslit forte","genericName":"Allerslit forte","companyName":"Allergopharma GmbH & Co. KG","companyId":"allergopharma-gmbh-co-kg","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allerslit forte is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual exposure to increasing doses. Used for Allergic rhinitis and/or allergic asthma caused by specific environmental allergens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}